Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 10Prostatic Neoplasms 7Sarcoma 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Urinary Bladder Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Breast Carcinoma In Situ 2Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Prostate Adenocarcinoma 1Pituitary Neoplasms 1Neurilemmoma 1Nerve Sheath Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1Male Urogenital Diseases 1Lymphedema 1

Interventions

Gemcitabine 15Cisplatin 15pembrolizumab 9Oxaliplatin 7durvalumab 5Leucovorin 5Fluorouracil 5130-nm albumin-bound paclitaxel 5Platinum 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4Trastuzumab 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Capecitabine 3zanidatamab 2fludarabine 2Paclitaxel 2Nivolumab 2Folfox protocol 2Docetaxel 2Cyclophosphamide 2Biopsy 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1pertuzumab 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × Radiation Dose Hypofractionation × 1 year × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡